that have advanced our knowledge of the predictive value of ED for CVD. The robustness of our findings is ensured by the overall population size of the present meta-analysis (92 757 subjects) and by the lengthy follow-up.
rectile dysfunction (ED) is a common clinical problem worldwide with thousands of new cases each year. 1, 2 In the Massachusetts Male Aging Study, the prevalence of ED was 52% in men 40 to 70 years of age and 70% in men >70 years of age.
3 Cardiovascular (CV) disease (CVD) and ED share common risk factors, 4 whereas evidence-based studies have identified pathophysiological links between ED and other vascular diseases, such as endothelial dysfunction and inflammation, 5, 6 thus identifying ED as an appealing candidate marker for future CV events. Screening and diagnosing ED could be of great importance for primary prevention because ED assessment offers an easy, low-cost alternative to several investigational CV biomarkers and could describe the risk over and beyond traditional risk factors, particularly for those patients belonging to the intermediate-CV-risk category. ED may precede clinically overt CVD by 2 to 5 years, 6 providing a valuable time window for earlier modification of risk factors and potential improvement in outcomes. Importantly, studies have implicated that improvement of ED and ED-associated comorbidities by either pharmacological or lifestyle interventions might be beneficial in terms of prognosis. 6 A number of studies examined the ability of ED to predict the risk of future fatal and nonfatal CV events and all-cause mortality. Although there is a general impression that ED has an important predictive role based on the results of individual studies, the overall quantitative estimate of this role has not been fully clarified, 30, 31 and implementation in clinical practice is suboptimal. In addition, because most studies yielded positive results, publication bias may have been involved. Finally, an important issue is whether the predictive ability of ED extends beyond CV events. Accordingly, we conducted the present study to calculate robust quantitative estimates of the predictive value of ED for different outcomes. Second, we investigated whether publication bias could have affected the true predictive ability of ED. Third, we evaluated clinically meaningful issues such as the effect of different baseline CV risk factors and of different diagnostic methods for ED (eg, questionnaire versus single question) on the predictive ability of ED. Toward this end, we included new landmark studies 20, 27 
Methods
The meta-analysis was conducted according to the checklist of the Meta-analysis of Observational Studies in Epidemiology. 32 Outcomes of interest were (1) total CV events, (2) CV mortality, (3) myocardial infarction (MI), (4) cerebrovascular events (stroke, transient ischemic attacks, intracranial hemorrhage), and (5) all-cause mortality. Total CV events were defined as CV death, MI, revascularization, cerebrovascular events, peripheral vascular disease, angina, heart failure, and arrhythmia.
Data Sources and Searches
Studies were drawn from a systematic review of the literature in the PubMed, Cochrane, and Embase databases until July 2012. The search terms are cited in the online-only Data Supplement. Data sources were also identified through a manual search of the references of articles.
Study Selection
Studies were deemed eligible on the following conditions: (1) if they were full-length publications in peer-reviewed journals; (2) if they evaluated ED (for details, see Table I in the online-only Data Supplement); (3) if they reported a combined CV outcome or a separate outcome such as CV mortality, MI, cerebrovascular event and all-cause mortality; (4) if the follow-up period was at least 1 year; and (5) if they were longitudinal cohort studies, either retrospective or prospective. Studies with cancer patients were excluded from our meta-analysis. Otherwise, no restriction criteria were imposed with regard to the type of the population studied (general population or populations with risk factors or disease) or to the size of the population. All but 3 longitudinal studies (4 articles) 7, 8, 11, 26 included in the meta-analysis were prospective studies. Retrospective studies were intentionally included (see Discussion for rationale).
Data Extraction and Quality Assessment
The literature search, selection of studies, quality assessment (for details, see the online-only Data Supplement), and extraction of data were done independently by 2 reviewers (C.V.V., D.G.T-P.). Disagreements were resolved by consensus. For each study, we recorded a risk estimate for ED. Numeric data appearing in the articles were used.
Data Synthesis and Analysis
The risk estimates of each study were reported as hazard ratio, relative risk (RR), odds ratio, or dichotomous frequency data. We treated hazard ratios as RRs. When available, we used the adjusted-risk estimates from multivariate models. Of all available multivariate models, we chose the one that had adjusted for the largest number of possible clinically relevant confounding factors. We performed meta-analyses of studies investigating ED to obtain the pooled RRs separately for the following: (1) total CV events, (2) CV mortality, (3) MI, (4) cerebrovascular events, and (5) all-cause mortality. The proportion of inconsistency across studies not explained by chance was quantified with the I 2 statistic. Heterogeneity between subgroups was calculated with the Cochran Q test. 33 When significant heterogeneity existed among studies (P<0.05), the random-effects model was used to obtain the pooled RRs. We also calculated adjusted RRs of ED versus no ED groups in each study. We performed a sensitivity analysis to evaluate whether the strength of risk estimates differs between intermediaterisk groups (subjects with a 10-year risk of CVD between 10% and 20% based on Framingham Risk Score) and high-risk groups (subjects with CVD or diabetes mellitus and a 10-year risk of CVD >20% based on the Framingham Risk Score) or low-risk groups (subjects with a 10-year risk of CVD <10% based on the Framingham Risk Score) and between different methods of ED diagnosis (single question versus questionnaire). Risk estimates in subgroups were compared by use of a test of interaction. 34 The RRs and confidence intervals (CIs) of individual studies were illustrated with forest plots. To estimate the contribution of continuous study moderators to the overall heterogeneity, we ran a meta-regression analysis with fixed-effects estimates. When pooled RRs were statistically significant, the presence of publication bias was investigated graphically by funnel plots of precision, and its implications for our results were assessed by the Duval and Tweedie trim-and-fill method 35 and the classic fail-safe N method as introduced by Rosenthal. 36 All analyses were performed with comprehensive meta-analysis version 2 (Biostat, Englewood, NJ).
Results

Literature Search
Literature search results are shown in Figure 1 . We retrieved 8335 articles from our preliminary search. Of these, 23 were identified for full review. For details on the exclusion of studies 10, [22] [23] [24] [25] 28, 29 after full review, see the online-only Data Supplement.
Study Characteristics
Our meta-analysis included 16 original articles. In total, the included studies analyzed 92 757 subjects. Several populations such as patients with hypertension, diabetes mellitus, or coronary artery disease and subjects from the general population were included. Details of the individual studies are shown in 
Meta-analysis
ED and Total CV Events
The magnitude of risk in individuals who had ED was significantly higher compared with the risk of individuals without ED. The pooled RRs for ED were 1.44 (95% CI, 1.27-1.63) for total CV events ( Figure 2A ). By applying a sensitivity analysis, we excluded the 3 retrospective studies without significant changes in our final results for total CV events (RR, 1.42; 95% CI, 1.22-1.65; P<0.001).
Because we observed significant heterogeneity (I 2 =66.4%, P<0.001) among the included studies, we conducted betweenstudy subgroup analyses to investigate its sources. The RR was significantly different across studies with different baseline CV risk populations. (P=0.003; Figure 3 ). Specifically, the RR for ED was significantly higher in intermediate-risk 9, 12, 15, 19 populations compared with high-risk 13, 14, 20, 21 and low-risk 18, 27 populations (RR, 1.51; 95% CI, 1. To further investigate the incremental predictive role of ED above and beyond conventional risk factors, we performed a sensitivity analysis in which we included studies 9,12,14,19,21,27 that had adjusted for age, smoking, diabetes mellitus, cholesterol, and hypertension/blood pressure (as opposed to the remainder of the studies that had adjusted for only some of those parameters). The RR in these studies (RR, 1.41; 95% CI, 1.16-1.71; P<0.001) was similar to the overall combined estimated risk. Moreover, we applied a sensitivity analysis in which we included only high-quality studies as assessed by our quality analysis 9, 12, 13, [19] [20] [21] 27 with similar results (RR, 1.34; 95% CI, 1.17-1.54; P<0.001).
ED and CV Mortality, MI, and Cerebrovascular Events
The magnitude of risk for most clinical end points in individuals who had ED was significantly higher compared with the risk of individuals without ED, except for CV mortality, which showed a trend toward significance (P=0.089). The pooled RRs for ED were 1.19 (95% CI, 0.97-1.46), 1.62 (95% CI, 1.34-1.96), and 1.39 (95% CI, 1.23-1.57) for CV mortality, MI, and cerebrovascular events, respectively ( Figure 2B-2D ).
ED and All-Cause Mortality
The magnitude of risk in individuals who had ED was significantly higher compared with the risk in individuals without ED. The pooled RR for ED was 1.25 (95% CI, 1.12-1.39) for all-cause mortality ( Figure 2E ).
Because we observed heterogeneity (I 2 =31.9%; P=0.204) among the included studies, we conducted between-study subgroup analyses. The RR of ED patients for all-cause mortality was significantly higher in patients with known CVD 17, 20 compared with patients without (predominantly) known CVD 9, 16, 21 (RR, 1.90; 95% CI, 1.31-2.77 versus RR, 1.20; 95% CI, 1.07-1.34; P=0.021).
Publication Bias
The funnel plots were asymmetrical at the bottom ( Figure I in the online-only Data Supplement) for all end points, suggesting an absence of small studies with small or negative risk estimates in our meta-analysis. The trim-and-fill method imputed missing studies and recalculated our pooled risk estimate ( Figure IA -ID in the online-only Data Supplement). The imputed RR was 1.32 (95% CI, 1.16-1.51), 1.52 (95% CI, 1.28-1.80), 1.37 (95% CI, 1.21-1.54), and 1.20 (95% CI, 1.08-1.33) for total CV events, MI, cerebrovascular events, and all-cause mortality, respectively, which are lower than our original risk estimates but are still significant. Importantly, the results of the fail-safe N test of our pooled analysis are 300, 21, 34, and 22 respectively, which for all end points are reassuring. The fail-safe N test computes the number of missing studies (with a mean effect of zero) that would need to be added to the analysis to yield a statistically nonsignificant overall effect, and it is unlikely that there are >23 (300/13=23.1), >5 (21/4=5.3), >5 (34/6=5.7), and >4 (22/5=4.4) unpublished or undiscovered studies for every 1 study that we found for total CV events, MI, cerebrovascular events, and all-cause mortality, respectively. These findings suggest that the apparent publication bias is insufficient to affect our results or interpretations in a meaningful way.
Meta-regression Analysis
Age at enrollment was the strongest predictor of the magnitude of the log RR in ED patients and inversely related to the predictive role of ED for total CV events (P<0.001; Figure  4A ). Duration of follow-up was not a predictor (P=0.52). The percentage of smokers and total cholesterol in each study showed positive associations with the predictive role of ED (P=0.003 and P=0.001, respectively), and pulse pressure, HDL, and BMI showed inverse associations with the predictive role of ED (P=0.03, P=0.01, and P=0.02, respectively), whereas inverse associations of percentage of diabetics and systolic blood pressure with the predictive role of ED were not statistically significant or showed a trend (P=0.29 and P=0.07, respectively; Figure 4A -4H). Exclusion of outliers had minimal effects on the above-mentioned results.
Discussion
In this systematic review and meta-analysis, we pooled the data for 92 757 subjects investigated for ED from 16 available published articles who were followed up for a mean of 6.1 years. Our study is the first to investigate in a thorough manner whether the presence of ED increases the risk for future events and to assess factors influencing such a predictive ability. Our principal finding is that patients with ED compared with subjects without ED have a significantly increased risk by 44% for total CV events, 62% for MI, 39% for cerebrovascular events, and 25% for all-cause mortality. The risk for CV mortality was also increased by 19%, but this increase only showed a trend toward significance. Importantly, the RR is higher in younger patients and in patients with intermediate CV risk. Furthermore, diagnosis of ED by a questionnaire is associated with a higher RR compared with diagnosis of ED with a single question. Finally, the RR increases with increased percentage of smokers, decreased pulse pressure, and deteriorated dyslipidemic profile.
Clinical Implications
Our findings are potentially applicable to clinical practice. First, they support inclusion of ED by the European guidelines for CVD prevention. 37 Our analysis showed that the risk conferred by ED on events is of a magnitude similar to that of the risk conferred on events by established risk predictors such as hypertension and dyslipidemia commonly encountered in clinical practice. Thus, our results stress the importance of early diagnosis of ED and the meticulous CV investigation that is required in specific groups of ED patients. 38 Furthermore, an important finding of our analysis is that ED is a significant predictor of all-cause mortality in addition to CV outcomes. Interestingly, ED is a stronger predictor of all-cause mortality in patients with known CVD compared with patients without CVD. Although pathophysiological explanations are not readily identifiable, this predictive ability for all-cause mortality could reflect the existence of common pathogenetic mechanisms such as aging, inflammation, and oxidative stress over a wide range of conditions. Moreover, rates of depression are increased in patients with CVD and ED. Depression worsens the outcome of comorbid physical conditions, and depressed patients show decreased adherence to treatment.
Improvement of ED by lifestyle interventions per se might be beneficial in terms of prognosis, 14, 39, 40 and our results highlight the role of ED as a potential low-cost biomarker that would call for more aggressive CV risk factor modification. 41 Of special interest is the effect of pharmacological treatment of ED, because it seems that this may also have a beneficial impact on risk. Indeed, Frantzen et al 11 showed that 2 years after the introduction of sildenafil, the RR of the incidence of CVD among men with ED compared with healthy men significantly decreased from 1.7 to 1.1. Furthermore, Gazzaruso et al 14 showed that type 5 phosphodiesterase inhibitors offer marginal protection against the development of major adverse cardiac events in diabetic patients with coronary artery disease and ED. Undoubtedly, more data are needed, and future follow-up studies should ideally collect information on ED treatment and investigate such an effect.
Further dissection of our principal finding provided interesting information. The RR was higher in patients with intermediate baseline CV risk compared with ED patients with high or low CV risk. This is particularly important because this intermediate-risk group is in need of further risk reclassification with a predictor such as ED. Furthermore, the RR was higher in younger ED patients despite the fact that the probability of ED increases with age. In fact, ED as a predictor may be particularly useful in these young patients in whom the Framingham Risk Score may underestimate risk by examining forward only 10 years. 42 In addition to younger age, the RR was higher in the presence of smoking and dyslipidemic profile. Although risk factors become more frequent with advancing age, we interpret these findings as being complementary rather than contradictory. Overall, this combination of younger age and multiple risk factors may imply an aggressive pathophysiological background that is exacerbated by environmental factors such as smoking and unhealthy diet and stresses the necessity for their identification and treatment in patients with ED.
Our study provides interesting caveats for the heterogeneity of methods used across studies to diagnose ED. Although the medical and sexual history is essential and frequently the most revealing aspect of the ED assessment process, the diagnostic potential of assessment questionnaires has certain limits. The use of a validated questionnaire such as the International Index of Erectile Function questionnaire, which has been widely used for assessment of presence and severity ED and has been shown to correlate with Gensini score in patients undergoing coronary angiography, 43 improves the diagnosis of ED and is the preferred strategy; however, this is not universally adopted. The importance of the use of a validated questionnaire is supported by our findings that in patients in whom ED was diagnosed with a questionnaire, the RR for total CV events was higher compared with that in patients in whom ED was diagnosed with a single question. Thus, it seems reasonable that ED when better substantiated and carefully investigated could provide more useful information about the future CV risk of the ED patient.
Of the studies included in the analysis, 5 used a validated questionnaire, 14, 15, [18] [19] [20] and of these, only 3 reported data according to the severity of ED. [18] [19] [20] Two more studies, 12,23 despite using a single question to assess ED, categorized the answers according to ED severity on a 3-point scale. Taken as a whole, this evidence points toward a grading effect of the severity of ED in the predictive ability of this condition for CV events. 12, 20, 23 However, more studies are needed to substantiate this notion.
Methodological Considerations
An important strength of our study is the exhaustive search strategy that likely enabled us to capture most, if not all, relevant studies. Moreover, our study for the first time uses data from the published studies for meta-regression analyses, thus enhancing the identification of the predictive role of ED in CVD. Furthermore, as a meta-analysis, the present study overcomes the potentially biased inclusion and weighing of results that may appear in reviews when interpreting the available evidence. Finally, although we would ideally want to have a larger number of high-quality studies, we dealt effectively with potential publication bias.
We intentionally included both prospective and retrospective longitudinal studies to allow a multifaceted approach to the estimation of risk. However, we took under consideration the more confounding and biased nature of retrospective studies. By applying a sensitivity analysis, we excluded these 3 retrospective studies without significant changes in our final results for total CV events.
In the majority of studies, ED patients were in most cases older, had higher blood pressure, and were more often diabetic or dyslipidemic. Thus, it is reasonable to assume that ED patients were a priori at higher baseline risk than non-ED patients. However, this inherent limitation of most prospective studies was dealt with in most of them by adjustment for the potential confounders between ED and non-ED patients. Furthermore, as it was shown in our sensitivity analysis for Relative risk (RR) of total cardiovascular events in patients with erectile dysfunction as a function of (A) age (data from 13 studies [7] [8] [9] [11] [12] [13] [14] [15] [18] [19] [20] [21] 26, 27 ), (B) smoking percentage in study population (data from 10 studies [7] [8] [9] [12] [13] [14] [18] [19] [20] [21] 27 ), (C) systolic blood pressure (data from 7 studies 9, 12, 13, [18] [19] [20] [21] ), (D) pulse pressure (data from 6 studies 9, 12, 13, 18, 20, 21 ), (E) cholesterol (data from 8 studies 9, [12] [13] [14] [18] [19] [20] [21] ), (F) high-density lipoprotein (data from 7 studies 9, [12] [13] [14] 18, 19, 21 ), (G) body mass index (data from 7 studies 9,12-14.18,19,21 ), and (H) diabetes mellitus percentage in study population (data from 10 studies 9, [12] [13] [14] [15] [18] [19] [20] [21] 27 ). Each study is represented by a circle that shows the actual coordinates (observed effect size by each of the above-mentioned variables) for that study. The size of each circle is proportional to the weight of the respective study in the analysis, that is, the inverse of the within-study variance for each study. The center line shows the predicted values by fixed-effects meta-regression. The vertical axis is on a log scale. adjustment of risk factors, the RR in studies that adjusted for all conventional risk factors was lower but not substantially different from the overall combined risk. Thus, it seems that the increased risk for ED patients is unlikely to be a consequence of the higher baseline CV risk of ED patients.
Our results are in accordance with the results of 2 previous meta-analyses 30, 31 that estimated the RR for CVD at 47% and 48%, respectively. However, these meta-analyses did not include landmark studies such as the VITAL (Vitamins and Lifestyle), 30 30 studies. Furthermore, in 1 study 31 results may have been influenced by a duplicate study inclusion (similar populations in the 2 studies) 19, 24 for the same end point, as well as by inclusion of a study 23 with a population made up exclusively of ED patients.
Links Between ED and Events
Because CVD and ED overlap in risk factors, prevalence, and manifestation, they are thought to share both pathophysiological basis of pathogenesis and progression. 4 The artery-size hypothesis 6, 43 proposes that the differential timing of the onset of signs (2-5 years) and symptoms of ED and CVD is caused by the difference between larger vessels and smaller ones (eg, pudendal or cavernous arteries) with regard to their ability to tolerate encroachment on the lumen. Moreover, we 6, 44 have shown that ED is associated with an incremental inflammatory and endothelial-prothrombotic activation on top of that found in patients with coronary artery disease. Accelerated arterial aging may be the background responsible for adverse outcome in ED, as pointed by the independent predictive ability of aortic stiffness (Vlachopoulos et al, unpublished observations) and pulse pressure (a crude index of aortic stiffness) 45 for events in ED patients. Moreover, low testosterone may be implicated in the common pathogenetic pathways of ED and CVD; however, this warrants further substantiation.
46-48
Study Limitations
We used aggregate data as reported in published articles (or calculated from other data provided in these) rather than individual data, and thus we could not deal with potential methodological problems of the original studies. Only 1 included study 19 provided robust estimates of the discriminatory and reclassification power of ED beyond classic risk factor or the Framingham Risk Score. The ability of ED to discriminate, calibrate, and reclassify risk can be assessed only on a patientlevel data analysis, which seems to be the next desirable step. Finally, although CV mortality and all-cause mortality were uniformly defined, the definition of total CV events differed among the studies included in the analysis.
Conclusions
The presence of ED increases the risk for future CV events, MI, cerebrovascular events, and all-cause mortality, whereas it shows a trend to increase risk for CV mortality. The RR is higher in young subjects, in subjects with intermediate baseline CV risk, and when ED is diagnosed by a questionnaire rather than a single question. These findings support implementation of ED into clinical practice and stress the need to establish standardized methods to diagnose ED and to investigate the potential effect of treatment of ED on CV events and all-cause mortality.
